Dianlong Jia

441 total citations
27 papers, 357 citations indexed

About

Dianlong Jia is a scholar working on Molecular Biology, Biomaterials and Immunology. According to data from OpenAlex, Dianlong Jia has authored 27 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Biomaterials and 8 papers in Immunology. Recurrent topics in Dianlong Jia's work include Nanoparticle-Based Drug Delivery (11 papers), RNA Interference and Gene Delivery (8 papers) and Immunotherapy and Immune Responses (6 papers). Dianlong Jia is often cited by papers focused on Nanoparticle-Based Drug Delivery (11 papers), RNA Interference and Gene Delivery (8 papers) and Immunotherapy and Immune Responses (6 papers). Dianlong Jia collaborates with scholars based in China, Netherlands and Germany. Dianlong Jia's co-authors include Qing Fan, Hao Yang, Xiaofeng Lu, Lin Wan, Huawei Cai, Fengjiao Yuan, Rui Li, Feifei Wang, Ze Tao and Lin Li and has published in prestigious journals such as Chemical Engineering Journal, ACS Applied Materials & Interfaces and Journal of Controlled Release.

In The Last Decade

Dianlong Jia

24 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dianlong Jia China 12 180 104 80 79 77 27 357
Ze Tao China 11 166 0.9× 123 1.2× 71 0.9× 75 0.9× 76 1.0× 37 378
Mark Prytyskach United States 9 207 1.1× 169 1.6× 102 1.3× 95 1.2× 51 0.7× 9 450
James R. Kintzing United States 7 481 2.7× 66 0.6× 100 1.3× 86 1.1× 131 1.7× 10 639
Eric A. W. van Dinther Netherlands 7 195 1.1× 114 1.1× 78 1.0× 64 0.8× 47 0.6× 11 410
Huafei Li China 12 159 0.9× 112 1.1× 133 1.7× 50 0.6× 36 0.5× 24 326
Emily Zheng United States 8 120 0.7× 236 2.3× 118 1.5× 95 1.2× 48 0.6× 16 479
Qiuxiao Shi China 11 138 0.8× 109 1.0× 61 0.8× 74 0.9× 79 1.0× 18 322
Tetsunari Kihira Japan 12 209 1.2× 44 0.4× 72 0.9× 63 0.8× 72 0.9× 16 393
Joseph J. Bellucci United States 7 207 1.1× 98 0.9× 172 2.1× 70 0.9× 41 0.5× 7 381
Thomas R. Dilling United States 10 119 0.7× 81 0.8× 56 0.7× 96 1.2× 189 2.5× 15 357

Countries citing papers authored by Dianlong Jia

Since Specialization
Citations

This map shows the geographic impact of Dianlong Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dianlong Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dianlong Jia more than expected).

Fields of papers citing papers by Dianlong Jia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dianlong Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dianlong Jia. The network helps show where Dianlong Jia may publish in the future.

Co-authorship network of co-authors of Dianlong Jia

This figure shows the co-authorship network connecting the top 25 collaborators of Dianlong Jia. A scholar is included among the top collaborators of Dianlong Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dianlong Jia. Dianlong Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Feifei, Dianlong Jia, Jun Li, et al.. (2025). Co-delivery of TRAIL and bortezomib via liposomes demonstrates enhanced antitumor efficacy in vivo. Journal of Drug Delivery Science and Technology. 105. 106602–106602.
2.
Yan, Lili, Lili Yi, Conghui Tian, et al.. (2025). TMEM176B inhibits ovarian cancer progression by regulating EMT via the Wnt/β-catenin signaling pathway. Journal of Translational Medicine. 23(1). 350–350.
3.
Chu, Xiaohong, Zhihan Liu, Wenjing Wang, et al.. (2025). Glycol Chitosan Modified Carbon Dots-Based Flower-like Nanoplatform for Synergistic Sterilization and Promoting Infected Wound Healing. ACS Applied Materials & Interfaces. 17(30). 42877–42892.
4.
Wang, Feifei, Yuxue Liu, Zi Chen, et al.. (2024). Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody. Molecular Pharmaceutics. 22(1). 284–294. 1 indexed citations
5.
Mu, Mengyao, Mengmeng Zhang, Kai Guo, et al.. (2024). A multifunctional nanoplatform capable of dual action on tumor PD-L1 for enhanced cancer theranostics. Chemical Engineering Journal. 502. 158139–158139. 1 indexed citations
6.
Jia, Dianlong, Shiqi Zhao, Huimin Liu, et al.. (2024). ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy. International Journal of Biological Macromolecules. 269(Pt 2). 132058–132058. 4 indexed citations
7.
Jia, Dianlong, Yue Lu, Feifei Wang, et al.. (2023). Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy. Journal of Controlled Release. 360. 858–871. 13 indexed citations
8.
Chang, Rui, Rongrong Fu, Jibing Zhang, et al.. (2023). Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors. Molecular Pharmaceutics. 20(6). 2864–2875. 6 indexed citations
9.
Chang, Rui, Xiaohong Chu, Jibing Zhang, et al.. (2023). Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules. 28(7). 3147–3147. 12 indexed citations
10.
Liu, Huimin, Dianlong Jia, Fengjiao Yuan, et al.. (2022). Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors. International Journal of Pharmaceutics. 617. 121609–121609. 15 indexed citations
11.
Jia, Dianlong, Feifei Wang, Yue Lü, et al.. (2022). Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors. International Journal of Pharmaceutics. 620. 121746–121746. 9 indexed citations
12.
Jia, Dianlong, Feifei Wang, Yujiao Yang, et al.. (2021). Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. Journal of Pharmaceutical Sciences. 111(2). 450–457. 8 indexed citations
13.
Wang, Haijun, Dianlong Jia, Dandan Yuan, et al.. (2021). Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. Journal of Nanobiotechnology. 19(1). 138–138. 34 indexed citations
14.
Jia, Dianlong, Yujiao Yang, Fengjiao Yuan, et al.. (2020). Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. International Journal of Pharmaceutics. 586. 119541–119541. 19 indexed citations
15.
Fan, Qing, Ze Tao, Hao Yang, et al.. (2019). Modulation of pericytes by a fusion protein comprising of a PDGFRβ-antagonistic affibody and TNFα induces tumor vessel normalization and improves chemotherapy. Journal of Controlled Release. 302. 63–78. 20 indexed citations
16.
Yang, Hao, Yanru Feng, Huawei Cai, et al.. (2018). Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects. Theranostics. 8(9). 2459–2476. 24 indexed citations
17.
Li, Rui, Hao Yang, Dianlong Jia, et al.. (2016). Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. Journal of Controlled Release. 228. 96–106. 73 indexed citations
18.
Su, Tao, Hao Yang, Qing Fan, et al.. (2016). Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier. International Journal of Pharmaceutics. 499(1-2). 195–204. 17 indexed citations
19.
Jia, Dianlong, Hao Yang, Ze Tao, et al.. (2015). Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta. Applied Microbiology and Biotechnology. 100(7). 3035–3047. 9 indexed citations
20.
Tao, Ze, Hao Yang, Dianlong Jia, et al.. (2013). Molecular cloning, recombinant expression and characterization of GMCSF from the rhesus monkey, Macaca mulatta. Developmental & Comparative Immunology. 40(1). 69–77. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ze Tao Breakdown of academic impact, for papers by Mark Prytyskach Breakdown of academic impact, for papers by James R. Kintzing Breakdown of academic impact, for papers by Eric A. W. van Dinther Breakdown of academic impact, for papers by Huafei Li Breakdown of academic impact, for papers by Emily Zheng Breakdown of academic impact, for papers by Qiuxiao Shi Breakdown of academic impact, for papers by Tetsunari Kihira Breakdown of academic impact, for papers by Joseph J. Bellucci Breakdown of academic impact, for papers by Thomas R. Dilling
Rankless by CCL
2026